BGM0504

Phase 3Small molecule

BBrightGene Bio-Medical Technology Co., Ltd.

BGM0504 is one of 118 small molecule programs targeting Overweight/Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overweight/obesityRecruiting

Overweight or ObeseNot yet recruiting

Type 2 Diabetes (T2DM)Recruiting

OverweightRecruiting

Type 2 DiabetesRecruiting

ObesityRecruiting

Overweight/obesityPhase 1

Recruiting

Overweight or ObesePhase 2

Not yet recruiting

Type 2 Diabetes (T2DM)Phase 3

Recruiting

OverweightPhase 1

Recruiting

Type 2 DiabetesPhase 3

Recruiting

ObesityPhase 2

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Retatrutide

Eli Lilly

Phase 3

6 2

Decadron

AAspen Global Incorporated

Phase 3

2 3

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 5

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

BGM0504

BBrightGene Bio-Medical Technology Co., Ltd.

Phase 3

1 7

Zenagamtide

Novo Nordisk

Phase 3

3 8

Berobenatide

Pfizer

Phase 3

3 9

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

1 10

Avapro

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Overweight or Obese

NCT07658560

Q4 2028

Phase 3Recruiting

Type 2 Diabetes (T2DM)

NCT07743983

Clinical

Trials by Indication[1]

Overweight4 trials

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07166081·80 enrolled

A Study of BGM0504 in Overweight or Obese Participants

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06920056·28 enrolled

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Recruiting·BBrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.·Phase 3·NCT06704581·620 enrolled

Show 1 more trial

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07239973·75 enrolled

Type 2 Diabetes2 trials

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06974825·67 enrolled

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 3·NCT07064486·477 enrolled

Obesity1 trial

A Study of BGM0504 in Participants With Obesity

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06911203·90 enrolled

Impaired Renal Function1 trial

A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06929156·34 enrolled

Weight loss1 trial

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06973681·120 enrolled

3 more indications

Type 2 Diabetes (T2DM)1 trial

A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1）

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 3·NCT07743983·372 enrolled

Overweight or Obese1 trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes

Not yet recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT07658560·200 enrolled

Unspecified1 trial

Bioequivalence Study of BGM0504 Injection

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT07382908·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for BGM0504. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGM0504 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGM0504. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BrightGene Bio-Medical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBrightGene Bio-Medical Technology Co., Ltd.

BGM0504

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Overweight4 trials

Type 2 Diabetes2 trials

Obesity1 trial

Impaired Renal Function1 trial

Weight loss1 trial

Type 2 Diabetes (T2DM)1 trial

Overweight or Obese1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News